SYS-CON MEDIA Authors: Yeshim Deniz, Doug Masi, Mat Mathews, PR.com Newswire, David Smith

News Feed Item

Investigation Report on China Epoetin Alfa Market, 2009-2018

DUBLIN, March 28, 2014 /PRNewswire/ --

Dublin - Research and Markets (http://www.researchandmarkets.com/research/8zbxmj/investigation) has announced the addition of the "Investigation Report on China Epoetin Alfa Market, 2009-2018" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Epoetin alfa refers to erythropoietin (EPO), a hormone-like substance secreted by kidney and liver that stimulates erythropoiesis. Indications of EOP approved in China are renal anemia, anemia after chemotherapy and surgery perioperative red blood cell mobilization.

The ratio between EPO used in renal dialysis and in chemotherapy is 3:1. Growth rate of EPO used in chemotherapy is about 20% to 25%, which is higher than that of renal dialysis. However, in the international market, more EPO is used in anemia after chemotherapy than in renal dialysis. This indicates huge market space for EPO used in anemia after chemotherapy in China.

Originally developed by Amgen Inc., epoetin alfa was approved to the U.S. in June 1989 by FDA with the trade name ""Epogen"". It is sold in over 40 countries now. Amgen is the only authorized product sold in the U.S. hemodialysis market. However, in other indications' market in the U.S., due to financial shortage, Amgen gave the marketing right of Epogen to Kirin-Amgen, Inc. (joint venture of Amgen and Kirin). The company then authorized Ortho Pharmaceutical Corporation of Johnson & Johnson to sell the product with the brand name ""Procrit"". In other countries including Chinese mainland, Taiwan and Japan, the drug is sold by Kirin Inc. and Johnson & Johnson with the trade names ""Espo"" and ""Eprex"" respectively. Both the companies are authorized by Kirin-Amgen.

Domestic enterprises took more than half of Chinese EPO market, leading to a market dominated by domestic EPO. According to CRI's market investigation on Chinese sample hospital market, ""Yi Bi Ao"" produced by Shenyang Sunshine Pharmaceutical Co., Ltd. seizes more than half of the EPO market. Kirin Brewery takes more than 10% market share while the other is occupied by other Chinese manufacturers.

As manufacturing technique improves and cost declines as well as Chinese people's affordability increases, EPO is no longer as expensive as it was 10 years ago. However, due to expansion of communities and rural markets in China, more market space is provided for EPO to develop. The sales revenue of EPO in 2013 was more than CNY 1 billion in Chinese hospital market. Incidence of chronic kidney diseases among Chinese adults is over 10% with more than 140 million patients.


Key Topics Covered:

1 Relevant Concepts of Epoetin Alfa

2 Market Overview of Epoetin Alfa in China

3 Investigation on Sales Value of Epoetin Alfa in China, 2009-2013

4 Investigation on Market Share of Major Epoetin Alfa Manufacturers in China, 2009-2013

5 Investigation on Market Size of Epoetin Alfa by Dosage Form in China, 2009-2013

6 Reference Price of Epoetin Alfa Produced by Different Enterprises in China Hospital Market

7 Analysis on Major Epoetin Alfa Manufacturers in China, 2009-2013

8 Prospect of China Epoetin Alfa Market, 2014-2018


Companies Mentioned: 

  • Beijing Sihuan Biopharmaceutical
  • Harbin Pharmaceutical Group Bio-Engineering
  • Kirin Brewery Company, Limited
  • Kyowa Hakko Kirin China Pharmaceutical
  • NCPC GeneTech Biotechnology development
  • Shandong Kexing Bioproducts
  • Shanghai Chemo Wanbang Biopharmaceutical
  • Shenyang Sunshine Pharmaceutical


For more information visit http://www.researchandmarkets.com/research/8zbxmj/investigation


Media Contact: Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.